Swiss biotech Therachon has expanded its rare disease pipeline after acquiring GLyPharma Therapeutic for an undisclosed amount.
Therachon said the “transformational” deal grants exclusive development and commercialisation rights to apraglutide – a next-gen synthetic GLP-2 analogue targeting short bowel syndrome (SBS) and other rare gastinal intestinal diseases.
Apraglutide was discovered by Ferring Pharmaceuticals and exclusively licences to GLyPharma back in 2012.
This follows a $60 million financing led by Novo Holdings in August.
“Expanding our pipeline with this new asset supports our mission of harnessing internal and external scientific innovation to make a difference in the lives of people living with serious rare conditions,” said Luca Santarelli, Therachon CEO.
“Like achondroplasia, our other area of focus, people living with SBS have significant unmet medical needs.
“We believe apraglutide offers a potential best-in-class profile for efficacy, as well as a favourable dosing regimen and improved tolerability compared with other GLP-2 analogues.”